Statin myopathy: The fly in the ointment for the prevention of cardiovascular disease in the 21st century?

Expert Opinion on Drug Safety

Volumn 13, Issue 9, 2014, Pages 1227-1239

  Keen, Helen I ^a   Krishnarajah, Janakan ^b   Bates, Timothy R ^a   Watts, Gerald F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

Cardiovascular disease; Muscle aches; Rhabdomyolysis; Side effects; Statin myopathy

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; DRUG THERAPY; EXPERIENCE; HEART PROTECTION; HUMAN; META ANALYSIS (TOPIC); MYOPATHY; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; SYSTEMATIC REVIEW (TOPIC); CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DOSE RESPONSE; MORTALITY; MUSCULAR DISEASES; RISK FACTOR;

CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; RISK FACTORS;

EID: 84906223844     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.937422     Document Type: Review

References (71)

1. LaRosa JC, Deedwania PC, Shepherd JC, et al. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the treating to new targets [TNT] trial). Am J Cardiol 2010;105(3):283-7
2. West of Scotland coronary prevention study: implications for clinical practice. The WOSCOPS study group. Eur Heart J 1996;17(2):163-4
3. Gomez Sandoval YH, Braganza MV, Daskalopoulou SS. Statin discontinuation in high-risk patients: a systematic review of the evidence. Curr Pharml Des 2011;17(33):3669-89
4. Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother 2009;10(18):2973-85
5. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009;150(12):858-68
6. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/ NHLBI clinical advisory on the use and safety of statins. Stroke 2002;33(9):2337-41
7. Baker SK, Vladutiu GD, Peltier WL, et al. Metabolic myopathies discovered during investigations of statin myopathy. Can J Neurol Sci 2008;35(1):94-7
8. Mancini GB, Baker S, Bergeron J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a canadian working group consensus conference. Can J Cardiol 2011;27(5):635-62
9. Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: canadian working group consensus update. Can J Cardiol 2013;29(12):1553-68
10. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 2013;158(7):526-34
11. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005;19(6):403-14
12. Law M, Rudnica AR. Statin safety: a systematic review. Am J Cardiol 2006;97(8A)):52C-60C
13. Mastaglia FL, Needham M. Update on toxic myopathies. Curr Neurol Neurosci Rep 2012;12(1):54-61
14. Mammen A, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011;63(3):713-21
15. Mammen AL, Gaudet D, Brisson D, et al. Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme a reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken) 2012;64(8):1233-7
16. Riphagen IJ, van der Veer E, Muskiet FA, DeJongste MJ. Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D. Curr Med Res Opin 2012;28(7):1247-52
17. Buettner C, Davis RB, Leveille SG, et al. Prevalence of musculoskeletal pain and statin use. J Gen Intern Med 2008;23(8):1182-6
18. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding statin use in america and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 2012;6(3):208-15
19. Rosenbaum D, Dallongeville J, Sabouret P, Bruckert E. Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutr Metab Cardiovasc Dis 2013;23(9):871-5
20. Amend KL, Landon J, Thyagarajan V, et al. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population. Ann Pharmacother 2011;45(10):1230-9
21. Finegold JA, Manisty CH, Goldacre B, et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol 2014;21(4):464-74
22. Maningat P, Breslow JL. Needed: pragmatic clinical trials for statin intolerant pateints. N Engl J Med 2011;365(24):2250-1
23. Joy TR, Monjed A, Zou GY, et al. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med 2014;160(5):301-10
24. Goh IX, How CH, Tavintharan S. Cytochrome P450 drug interactions with statin therapy. Singapore Med J 2013;54(3):131-5
25. Backman JT, Kyrklund C, Kivisto KT, et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000;68(2):122-9
26. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004;75(5):455-63
27. Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/ OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004;311(1):228-36
28. Ito MK, Maki KC, Brinton EA, et al. Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study Original Research Article. J Clin Lipidol 2014;8(1):69-76
29. Vladutiu GD, Simmons Z, Isacson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006;34(2):153-62
30. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/ NHLBI clinical advisory on the use and safety of statins. Stroke 2002;33:2337-41
31. Vladutiu GD. Genetic predisposition to statin myopathy. Curr Opin Rheumatol 2008;20(6):648-55
32. Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord 2014;24(1):4-15
33. Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54(17):1609-16
34. Niemi M, Pasanen M, Neuvonen P. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011;63(1):157-81
35. White C. Statin induced myopathy. SEARCH genome study's results. BMJ 2008;337:a2792
36. Ruano G, Windemuth A, Wu AH, et al. Mechanisms of statin-induced myalgia assessed by physiogenomic associations. Atherosclerosis 2011;218(2):451-6
37. Ruaño G, Thompson PD, Windemuth A, et al. Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve 2007;36(3):329-35
38. Calero M, Chen CZ, Zhu W, et al. Dual prenylation is required for Rab protein localization and function. Mol Biol Cell 2003;14(5):1852-67
39. Greenwood L, Steinman S, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006;6(5):358-70
40. Grosshans L, Ortiz D, Novick P. Rabs and their effectors: achieving specificity in membrane traffic. Proc Natl Acad Sci USA 2006;103(32):11821-7
41. Gomes AQ, Ali BR, Ramalho JS, et al. Membrane targeting of rab. GTPases is influenced by the prenylation motif. Mol Biol Cell 2003;14(5):1882-99
42. Schouten O, Hoeks SE, Welten GM, et al. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol 2007;100:316-20
43. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Available from: http://publications.nice.org.uk/lipid-modification- cg67/guidance
44. Collins GS, Altman DG. Predicting the adverse risk of statin treatment: an independent and external validation of Qstatin risk scores in the UK. Heart 2012;98:1091-7
45. Blaier O, Lishner M, Elis A. Managing statin-induced muscle toxicity in a lipid clinic. J Clin Pharm Ther 2011;36(3):336-41
46. Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J 2013;166(3):597-603
47. Glueck CJ, Budhani SB, Masineni SS, et al. Goldenberg N: vitamin d deficiency, myositis-myalgia, and reversible statin intolerance. Curr Med Res Opin 2011;27(9):1683-90
48. Naba H, Kakinuma C, Ohnishi S, Ogihara T. Improving effect of ethyl eicosapentanoate on statin-induced rhabdomyolysis in Eisai hyperbilirubinemic rats. Biochem Biophys Res Commun 2006;340(1):215-20
49. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365(24):2255-67
50. Blaier O, Lishner M, Elis A. Managing statin-induced muscle toxicity in a lipid clinic. J Clin Pharm Ther 2011;36(3):336-41
51. Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010;105(2):198-204
52. Rhodes T, Norquist JM, Sisk CM, et al. The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy. Int J Clin Pract 2013;67(12):1238-46
53. Jones MR, Nwose OM. Role of colesevelam in combination lipidlowering therapy. Am J Cardiovasc Drugs 2013;13(5):315-23
54. Childress L, Gay A, Zargar A, Ito MK. Review of red yeast rice content and current Food and Drug Administration oversight. J Clin Lipidol 2013;7(2):117-22
55. Sullivan D, Olsson AG, Scott R, et al. Effect of AMG. 145, a monoclonal antibody to PCSK9, on LDL cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012;308:2497-506
56. Hiatt WR, Smith RJ. Assessing the clinical benefits of lipid-disorder drugs. N Engl J Med 2014;370(5):396-9
57. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292(21):2585-90
58. Naka T, Jones D, Baldwin I, et al. Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report. Crit Care 2005;9(2):R90-5
59. Zimmerman JL, Shen MC. Rhabdomyolysis. Chest 2013;144(3):1058-65
60. Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med 2011;78(6):393-403
61. Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation 2013;127(1):96-103
62. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267-78
63. Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the statin muscle safety task force: 2014. update. J Clin Lipidol 2014;8:S58-71
64. Ruano G, Thompson PD, Windemuth A, et al. Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics 2005;6(8):865-72
65. Young JM, Florkowski CM, Molyneux SL, et al. Effect of coenzyme Q(10) supplementation on simvastatininduced myalgia. Am J Cardiol 2007;100(9):1400-3
66. Fedacko J, Pella D, Fedackova P, et al. Coenzyme Q(10) and selenium in statin-associated myopathy treatment. Can J Physiol Pharmacol 2013;91(2):165-70
67. Parker BA, Gregory SM, Lorson L, et al. A randomized trial of coenzyme Q10 in patients with statin myopathy: rationale and study design. J Clin Lipidol 2013;7(3):187-93
68. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007;99(10):1409-12
69. Mabuchi H, Nohara A, Kobayashi J, et al. Effects of coq10 supplementation on plasma lipoprotein lipid, coq10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis 2007;195(2):e182-9
70. Bookstaver DA, Burkhalter NA, Hatzigeorgiou C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Am J Cardiol 2012;110(4):526-9
71. Bogsrud MP, Langslet G, Ose L, et al. No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy. Scand Cardiovasc J 2013;47(2):80-7